Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow Quality Index
Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow Quality Index of 0.64x as of December 2025. Operating cash flow of ₩87.00 Billion is below net income of ₩136.59 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore 326030 cash generation efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sk Biopharmaceuticals Co Ltd Cash Flow Quality Index (2021–2025)
Historical Cash Flow Quality Index for Sk Biopharmaceuticals Co Ltd across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check total reinvestment intensity of Sk Biopharmaceuticals Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Sk Biopharmaceuticals Co Ltd (2021–2025)
Year-by-year earnings quality comparison for Sk Biopharmaceuticals Co Ltd. For live market cap and the full company financial profile, see Sk Biopharmaceuticals Co Ltd market cap and net worth.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | ₩176.33 Billion | ₩266.95 Billion | ▲ +67.6% |
| 2024 | 0.39x | ₩94.90 Billion | ₩240.74 Billion | ▲ +127.5% |
| 2021 | -1.43x | ₩-92.87 Billion | ₩64.85 Billion | — |